ACRS Stock Analysis: Buy, Sell, or Hold?
ACRS - Aclaris Therapeutics, Inc.
$5.56
0.22 (4.12%)
▲
5d:
+13.24%
30d:
+20.09%
90d:
+34.3%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ACRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ACRS is 11.2% above its trading range ($5.00). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ACRS is 11.2% above its trading range ($5.00). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ACRS is currently trading at $5.56, which is considered extended relative to its 30-day fair value range of $4.29 to $5.00.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is approaching resistance at $5.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: ACRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+79.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is approaching resistance at $5.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: ACRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+79.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.29 -
$5.00
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+11.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 79.9% below Wall St target ($10.00)
Trading Range Analysis
30-Day Trading Range
$4.29 -
$5.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.37
Resistance Level
$5.69
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.71
Wall Street Target
$10.00
(+79.9%)
Revenue Growth (YoY)
37.2%
Share & Embed Analysis
Last updated: July 02, 2026 9:41 PM ET
Data refreshes hourly during market hours. Next update: 10:41 PM
Data refreshes hourly during market hours. Next update: 10:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ACRS is a key holding in these high-performance investment strategies.
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
